Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events
Authors: Frederick A. Spencer, Gordon Guyatt
Journal: Annals of Internal Medicine (2015)

ACP Journal Club17 March 2015Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular eventsFrederick A. Spencer, MD, Gordon Guyatt, MDFrederick A. Spencer, MDMcMaster University, Hamilton, Ontario, Canada (F.A.S., G.G.)Search for more papers by this author, Gordon Guyatt, MDMcMaster University, Hamilton, Ontario, Canada (F.A.S., G.G.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2015-162-6-009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66. https://pubmed.ncbi.nlm.nih.gov/25399658Clinical Impact RatingsGIM/FP/GP: Cardiology: Hematology: References1. Collet JP, Silvain J, Barthélémy O, et al; ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577-85. [PMID: 25037988] Google Scholar2. Feres F, Costa RA, Abizaid A, et al; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-22. [PMID: 24177257] Google Scholar3. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-13. [PMID: 22179532] Google Scholar4. Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129:304-12. [PMID: 24097439] Google Scholar5. Valgimigli M, Borghesi M, Tebaldi M, et al; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34:909-19. [PMID: 23315904] Google Scholar Author, Article, and Disclosure InformationAuthors: Frederick A. Spencer, MD; Gordon Guyatt, MDAffiliations: McMaster University, Hamilton, Ontario, Canada (F.A.S., G.G.)This article was published at Annals.org on 3 March 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 March 2015Volume 162, Issue 6Page: JC9KeywordsAntiplatelet therapyAspirinDrug therapyDrugsHazard ratioHemorrhageMyocardial infarctionSafetyStent implantationThrombosis ePublished: 17 March 2015 Issue Published: 17 March 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...